New ovarian cancer drugs included in medical insurance experts: the average monthly out-of-pocket cost of patients is as low as two to three thousand yuan

As the "king of women's cancer", ovarian cancer has the highest mortality rate among gynecological malignancies, and it is also one of the tumors with the highest incidence of gynecological reproductive system.

According to data from the National Cancer Center, the 5-year survival rate for ovarian cancer has only increased by 0.

"Ovarian cancer has three cruelty 70% in clinical practice: 70% of patients are at an advanced stage once discovered; 70% of patients will relapse, which means that even after standard surgery and chemotherapy, most patients will still suffer within two years.

In recent years, in the field of ovarian cancer, with the advent and clinical application of PARP inhibitors, maintenance therapy has become a new standard treatment method and has attracted much attention, especially in patients with platinum-sensitive relapsed ovarian cancer, regardless of whether the patient has BRCA mutation or not.

In December last year, the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security officially announced the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2020)" which included 119 drugs, including 17 new anti-cancer drugs, including PD -1.

It is reported that Nirapali is the only new ovarian cancer drug added to the 2020 drug catalog.

Yao Shuzhong said: "Now we see that Guangdong is also stepping up the implementation of medical insurance policies, so that more local patients can afford and use the preferred anti-tumor drugs.